Shannon C Leonard
Overview
Explore the profile of Shannon C Leonard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leonard S, Lee H, Gaddy D, Klinz S, Paz N, Kalra A, et al.
Anticancer Drugs
. 2017 Sep;
28(10):1086-1096.
PMID: 28857767
Liposomal irinotecan (irinotecan liposome injection, nal-IRI), a liposomal formulation of irinotecan, is designed for extended circulation relative to irinotecan and for exploiting discontinuous tumor vasculature for enhanced drug delivery to...
2.
Lee H, Shields A, Siegel B, Miller K, Krop I, Ma C, et al.
Clin Cancer Res
. 2017 Mar;
23(15):4190-4202.
PMID: 28298546
Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly...
3.
Espelin C, Leonard S, Geretti E, Wickham T, Hendriks B
Cancer Res
. 2016 Jan;
76(6):1517-27.
PMID: 26759238
Trastuzumab is the standard of care for HER2-positive breast cancer patients, markedly improving disease-free and overall survival. Combined with chemotherapy, it enhances patient outcomes, but cardiotoxicity due to the trastuzumab...
4.
Reynolds J, Geretti E, Hendriks B, Lee H, Leonard S, Klinz S, et al.
Toxicol Appl Pharmacol
. 2012 Jun;
262(1):1-10.
PMID: 22676972
Anthracycline-based regimens are a mainstay of early breast cancer therapy, however their use is limited by cardiac toxicity. The potential for cardiotoxicity is a major consideration in the design and...